These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35060452)

  • 1. Immunotherapy for Gastroesophageal Tumors: Is there still Hope for Efficacy?
    Puhr HC; Ilhan-Mutlu A
    Curr Cancer Drug Targets; 2022 Aug; 22(8):651-666. PubMed ID: 35060452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolving Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancer.
    Murphy AG; Kelly RJ
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):485-498. PubMed ID: 28501089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.
    Bockorny B; Pectasides E
    Future Oncol; 2016 Aug; 12(15):1833-46. PubMed ID: 27166503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
    Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
    Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Immunotherapy in Advanced Gastroesophageal Cancer.
    Terrero G; Lockhart AC
    Curr Oncol Rep; 2020 Aug; 22(11):112. PubMed ID: 32803457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
    Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
    Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer.
    Bolm L; Käsmann L; Paysen A; Karapetis C; Rades D; Wellner UF; Keck T; Watson DI; Hummel R; Hussey DJ
    Anticancer Res; 2018 Jun; 38(6):3231-3242. PubMed ID: 29848670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesothelin Expression in Advanced Gastroesophageal Cancer Represents a Novel Target for Immunotherapy.
    Illei PB; Alewine C; Zahurak M; Cowan ML; Montgomery E; Hassan R; Xiang L; Pastan I; Kelly RJ
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):246-52. PubMed ID: 26894650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in gastroesophageal cancers: Current state and future directions.
    Shaikh H; Kamran A; Monga DK
    J Oncol Pharm Pract; 2021 Mar; 27(2):395-404. PubMed ID: 33050805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review.
    Chen K; Wang X; Yang L; Chen Z
    Cancer Control; 2021; 28():1073274821997430. PubMed ID: 33618535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the Management of Gastric and Gastroesophageal Cancers.
    Kamran SC; Hong TS; Wo JY
    Curr Oncol Rep; 2016 Feb; 18(2):13. PubMed ID: 26769118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological Features of Gastroesophageal Neuroendocrine Neoplasms.
    Liu M; Popa EC; Finnerty BM; Fahey TJ; Zarnegar R
    Curr Gastroenterol Rep; 2020 Aug; 22(10):50. PubMed ID: 32797314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targetting esophageal and gastric cancers with monoclonal antibodies.
    Norguet E; Dahan L; Seitz JF
    Curr Top Med Chem; 2012; 12(15):1678-82. PubMed ID: 22978338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.
    Vrána D; Matzenauer M; Neoral Č; Aujeský R; Vrba R; Melichar B; Rušarová N; Bartoušková M; Jankowski J
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [THE MAGIC OF IMMUNOTHERAPY - ANTI-PD1 TREATMENT IN ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION].
    Daskal N; Grinspun A; Godefroy J; Hubert A
    Harefuah; 2022 Jan; 161(1):17-20. PubMed ID: 35077054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Esophageal and Gastric Cancer.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers-A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference.
    Mulder K; Lim H; Ravi D; Ahmed S; Brunet B; Davies J; Doll C; Dueck DA; Gordon V; Hebbard P; Kim CA; Le D; Lee-Ying R; McGhie JP; Park J; Renouf DJ; Schellenberg D; Wong RPW; Zaidi A; Ahmed S
    Curr Oncol; 2022 Apr; 29(5):3160-3170. PubMed ID: 35621647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic Therapy in Gastroesophageal Cancer.
    Jin Z; Yoon HH
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):499-510. PubMed ID: 28501090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in immune-based approaches for the treatment of esophagogastric cancer.
    Weadick CS; Duffy AG; Kelly RJ
    Expert Opin Emerg Drugs; 2022 Mar; 27(1):19-31. PubMed ID: 34937483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.